Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Follow-Up Questions
Qui est le CEO de Genelux Corp ?
Mr. Thomas Zindrick est le Chairman of the Board de Genelux Corp, il a rejoint l'entreprise depuis 2014.
Quelle est la performance du prix de l'action GNLX ?
Le prix actuel de GNLX est de $8.23, il a increased de 1.54% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Genelux Corp ?
Genelux Corp appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Genelux Corp ?
La capitalisation boursière actuelle de Genelux Corp est de $311.0M
Est-ce que Genelux Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour Genelux Corp, y compris 2 achat fort, 8 achat, 1 maintien, 0 vente et 2 vente forte
